» Articles » PMID: 29695586

GREB1 Isoforms Regulate Proliferation Independent of ERα Co-regulator Activities in Breast Cancer

Overview
Specialties Endocrinology
Oncology
Date 2018 Apr 27
PMID 29695586
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of the transcription factor estrogen receptor α (ERα) and the subsequent regulation of estrogen-responsive genes play a crucial role in the development and progression of the majority of breast cancers. One gene target of ERα, growth regulation by estrogen in breast cancer 1 (), is associated with proliferation and regulation of ERα activity in estrogen-responsive breast cancer cells. The gene encodes three distinct isoforms: , and , whose molecular functions are largely unknown. Here, we investigate the role of these isoforms in regulation of ERα activity and proliferation. Interaction between GREB1 and ERα was mapped to the amino terminus shared by all GREB1 variants. Analysis of isoform-specific regulation of ERα activity suggests none of the GREB1 isoforms possess potent co-regulator activity. Exogenous expression of GREB1a resulted in elevated expression of some ER-target genes, independent of ERα activity. Despite this slight specificity of GREB1a for gene regulation, exogenous expression of either GREB1a or GREB1b resulted in decreased proliferation in both ER-positive and ER-negative breast carcinoma cell lines, demonstrating an ER-independent function of GREB1. Interestingly, we show an increase in the expression of GREB1b and GREB1c mRNA in malignant breast tissue compared to normal patient samples, suggesting a selective preference for these isoforms during malignant transformation. Together, these data suggest GREB1a has an isoform-specific function as a transcriptional regulator while all isoforms share an ER-independent activity that regulates proliferation.

Citing Articles

Interdependency of estradiol-mediated ERα activation and subsequent PR and GREB1 induction to control cell cycle progression.

Heldring M, Duijndam B, Kyriakidou A, van der Meer O, Tedeschi M, van der Laan J Heliyon. 2024; 10(21):e38406.

PMID: 39583845 PMC: 11582769. DOI: 10.1016/j.heliyon.2024.e38406.


Design, synthesis, and biological evaluation of indole-modified tamoxifen relatives as potent anticancer agents.

Ertugrul B, Aytatli A, Karatas O, Saracoglu N RSC Med Chem. 2023; 14(7):1362-1376.

PMID: 37484572 PMC: 10357932. DOI: 10.1039/d3md00157a.


CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3.

Porras L, Gorse F, Thiombane N, Gaboury L, Mader S Cancers (Basel). 2022; 14(21).

PMID: 36358871 PMC: 9657334. DOI: 10.3390/cancers14215453.


Comprehensive Analysis of GDF10 Methylation Site-Associated Genes as Prognostic Markers for Endometrial Cancer.

Fan J, Zhou H J Oncol. 2022; 2022:7117083.

PMID: 36262352 PMC: 9576415. DOI: 10.1155/2022/7117083.


PRMT1, a Key Modulator of Unliganded Progesterone Receptor Signaling in Breast Cancer.

Malbeteau L, Jacquemetton J, Languilaire C, Corbo L, Le Romancer M, Poulard C Int J Mol Sci. 2022; 23(17).

PMID: 36076907 PMC: 9455263. DOI: 10.3390/ijms23179509.


References
1.
Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

2.
Varley K, Gertz J, Roberts B, Davis N, Bowling K, Kirby M . Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Res Treat. 2014; 146(2):287-97. PMC: 4085473. DOI: 10.1007/s10549-014-3019-2. View

3.
Patterson A, Mo X, Shapiro A, Wernke K, Archer T, Burd C . Sustained reprogramming of the estrogen response after chronic exposure to endocrine disruptors. Mol Endocrinol. 2015; 29(3):384-95. PMC: 4347288. DOI: 10.1210/me.2014-1237. View

4.
Li J, Sun C, Li W, Chao R, Huang C, Zhou X . Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells. Nucleic Acids Res. 2015; 44(D1):D944-51. PMC: 4702907. DOI: 10.1093/nar/gkv1282. View

5.
Zacharewski T, Bondy K, McDonell P, Wu Z . Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced pS2 expression. Cancer Res. 1994; 54(10):2707-13. View